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Regular Article
IMMUNOBIOLOGY
Robust T-cell stimulation by Epstein-Barr virus–transformed B cells after
antigen targeting to DEC-205
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Key Points
• B cells contribute to MHC
presentation of DEC-205–
targeted antigen.
• Activated B cells present
DEC-205–targeted antigen
efficiently, because they retain
it longer.
DEC-205 is a type I transmembrane multilectin receptor that is predominantly expressed
on dendritic cells (DCs). Therefore, previous studies primarily focused on processing of
DEC-205–targeted antigens by this potent antigen presenting cell type. Here we show
that Epstein-Barr virus (EBV) transformed lymphoblastoid B-cell lines (LCLs) not only
express DEC-205 at similar levels to DCs, but also efficiently present targeted EBV
nuclear antigen 1 (EBNA1) and EBV-latent membrane protein 1 (LMP1) to EBNA1- and
LMP1-specific CD4 and CD8 T-cell clones in vitro. Targeting of antigens to DEC-205 on
B cells led to more efficient MHC class II than I loading, and stimulated T cells more
efficiently than targeting to DEC-205 on DCs. Although LCLs internalized DEC-205–
targeted antigens less efficiently than DCs, they retained them for longer time periods
and delivered them to endosomal compartments that receive also B-cell receptor
targeted proteins. This could facilitate prolonged T-cell stimulation and efficient MHC class II loading, and, indeed, CD4 T-cell
expansion by DEC-205–targeted vaccination was significantly compromised in B-cell deficient mice. These studies suggest that
B cells, activated by virus transformation or other means, can contribute to T-cell stimulation after DEC-205 targeting of antigens
during vaccination. (Blood. 2013;121(9):1584-1594)
Introduction
Dendritic cells (DCs) are sentinels of the immune system that
populate nearly all peripheral organs in their immature form.1 On
infection or encountering pathogen-associated molecular patterns
(PAMPs), DCs mature and migrate at enhanced frequency to
secondary lymphoid tissues. They transmit 2 types of information
to these immunologic decision centers. Firstly, they transfer
antigens from the site of activation and process these antigens for
presentation on major histocompatibility complex (MHC) mol-
ecules to T cells. Secondly, they communicate the conditions, under
which they have encountered these antigens via their maturation
pattern, which consists of up-regulated costimulatory molecules
and secretion of cytokines and chemokines. These 2 types of
transmitted information allow them to initiate the appropriate
immune response to the encountered pathogenic challenge, orches-
trating both innate and adaptive immunity.2,3 These potent antigen
presenting and immune stimulating functions make DCs an attrac-
tive tool for vaccination. However, adoptive DC therapy has only
provided limited success.4 Therefore, vaccination strategies are
currently being developed that target antigens to DCs in vivo. For
this purpose antibodies to endocytic, possibly antigen-uptake
receptors on DCs are coupled with antigen for injection together
with suitable immune activating adjuvants. Several C-type lectin
receptors, such as DEC-205, langerin, and Clec9a, have been
successfully used for immune response induction in mouse mod-
els5,6 and induce efficient human T-cell expansions in vitro.7-9
However, which other cell types, besides DCs, might contribute to
the immune response induction via C-type lectin-targeted antigens
remains largely unexplored.
Activated B cells are such antigen presenting cells that could
amplify DC-induced immune responses. One pathway for human
B-cell activation is transformation with the oncogenic -herpesvirus
Epstein-Barr virus (EBV).10 In EBV transformed B-cell lines,
so-called lymphoblastoid cell lines (LCLs), 8 latent EBV gene
products are expressed, including the 2 latent membrane proteins,
LMP2 and LMP1, which mimic constitutive signaling through the
B-cell receptor (BCR) and CD40 for B-cell activation.11 LMP1, in
particular, confers efficient antigen processing for MHC presenta-
tion and high surface levels of MHC molecules to LCLs.12,13
Because of this good antigen presenting function, LCLs have been
explored for purification of MHC ligands.14,15 Although LCLs have
a potent proteasome and TAP transporter associated MHC class I
ligand processing machinery, it remains largely unknown which
endocytic receptors are used to deliver extracellular antigens for
efficient MHC class II loading of LCLs. Apart from the BCR, only
Submitted August 17, 2012; accepted December 12, 2012. Prepublished
online as Blood First Edition paper, January 7, 2013; DOI 10.1182/blood-2012-
08-450775.
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’ in accordance with 18 USC section 1734.
© 2013 by The American Society of Hematology
1584 BLOOD, 28 FEBRUARY 2013  VOLUME 121, NUMBER 9
 For personal use only. at UNIVERSITAETSSPITAL on March 8, 2013. bloodjournal.hematologylibrary.orgFrom 
the complement receptor 2 (CR2 or CD21) and the Fc receptor II
have been suggested to lead to efficient antigen processing for
MHC class II presentation.16-18 Thus, it remains unclear whether
antigen targeting to certain endocytic receptors could harness both
DC priming and amplification of T-cell responses by virus or
otherwise activated B cells at the same time.
Here we show that LCLs efficiently present DEC-205–targeted
antigens to CD4 T cells of multiple specificities and HLA
restrictions. They are superior in this capacity to monocyte-derived
DCs, possibly because of their prolonged antigen retention and
efficient DEC-205–mediated transport to MHC class II loading
compartments, which also receive input from cross-linked BCR. In
addition, CD4 T-cell expansion by DEC-205–targeted vaccination
was significantly reduced in B-cell deficient mice. These data
suggest that activated B cells efficiently present antigens after
DEC-205–mediated uptake, and could amplify immune responses,
which are induced by DEC-205–targeted vaccination.
Methods
DEC-205-EBNA1, DEC-205-LMP1, and -mouse DEC-205-p24
monoclonal antibodies
The DEC-205 monoclonal antibodies (mAbs) used are described in
supplemental Methods (available on the Blood Web site; see the Supplemen-
tal Materials link at the top of the online article). The presented studies were
approved under institutional review board protocol KEK-StV-Nr. 19/08 and
ACUC protocol 148/2011. This study was conducted in accordance with the
Declaration of Helsinki.
T-cell assay
T-cell clones were generated and characterized as described.19 T-cell assays
were performed in triplicates by coculturing LCL cells (5  103/well) or
DCs (5  103/well) overnight with T cells (5  103/well) in 96-well
V-bottom plates. IFN released into the supernatant was measured by IFN
ELISA19 and the means plus SD are shown.
Flow cytometry
The details of flow cytometry analysis are described in supplemental
Methods.
Western blot
The preparation of protein extracts and Western blotting are outlined in
supplemental Methods.
Immunofluorescence
Immunofluorescence staining and imaging procedures are described in
supplemental Methods.
In vivo immunization
In vivo immunization of mice and intracellular cytokine staining were
performed according to the description in supplemental Methods.
Statistical analysis
Plotted data represent means plus SD, unless otherwise stated. P values
were calculated with the Mann-Whitney or Student t test.
Results
LCLs express DEC-205 and present DEC-205–targeted antigens
efficiently to T-cell clones of different peptide specificities and
HLA restrictions
To explore whether other immune cells could contribute to
DEC-205–targeted vaccination and because this receptor was
previously described to be expressed at moderate level on human
B cells20 and mouse B cells,21,22 we tested the DEC-205 expression
on human B-cell lines by staining with the 2 monoclonal DEC-205–
specific antibodies MG38.2 and 3G9 (supplemental Figure 1A;
data not shown).23,24 Surprisingly, DEC-205 was expressed at high
level on LCLs, the EBV positive Burkitt lymphoma B-cell line
RAJI and also on the EBV negative Burkitt lymphoma B-cell line
RAMOS. The expression level of DEC-205 on the B-cell lines was
even higher than on both mature and immature monocyte-derived
DCs. To investigate whether this high expression level can be used
for antigen processing, the mAb MG38.2 against human DEC-205
was fused with EBNA1 (aa 400-641) or LMP1 (aa 180-386). These
hybrid as well as isotype control fusion antibodies were produced,
characterized by silver staining and by Western blotting using
anti-EBNA1 or anti-LMP1 antibodies (supplemental Figure 1B).
To assess how well antigens can be presented after targeting to
DEC-205 on LCLs, we used EBNA1- or LMP1-specific CD4 or
CD8 T-cell clones raised from healthy EBV-positive donors. The
previously established CD4 T-cell clones against 4 EBNA1
epitopes, designated SNP restricted through HLA-DR51, VYG,
and PQC, both restricted through HLA-DR11, KTS restricted
through HLA-DR1, were incubated with HLA mismatched or
matched LCLs loaded with mAb fusion proteins or peptides, and
the respective T-cell responses were monitored by IFN produc-
tion. DEC-205-EBNA1–loaded LCLs induced strong T-cell re-
sponses, whereas the control isotype fusion antibody or DEC-205–
loaded matched LCLs did not. The T-cell responses of SNP- or
VYG-specific T-cell clones against LCLs loaded with DEC-205-
EBNA1 were even higher than LCLs loaded with the same
concentration of the cognate peptide epitopes (Figure 1A). PQC
presentation was least efficient, and this might reflect the partial
susceptibility of the PQC epitope sequence to destructive process-
ing by lysosomal proteases.19 Low production of IFN was also
observed for the KTS epitope, so we assessed the susceptibility of
these 2 epitopes to lysosomal degradation by cathepsins with the
program SitePrediction (www.dmbr.ugent.be/prx/bioit2-public/
SitePrediction/).25 PQC contained 6 predicted cuts (by cathepsins
B, G, K, and L), and might therefore be more susceptible to
lysosomal degradation than KTS with 3 predicted cuts (by cathep-
sins G, K, and L). DEC-205-EBNA1–loaded LCLs also induced a
higher CD8 T-cell response as seen with 2 EBNA1-specifc T-cell
clones against the HPV epitope restricted through HLA-B35
(Figure 1B), although the level of recognition was not as high as
observed for the CD4 T-cell responses in comparison with targets,
which were pulsed with the cognate peptide. The observed CD4
T-cell responses were especially remarkable considering the stoichi-
ometry of the used antigenic formulations. Because of the small
molecular weight of the used peptide epitopes, DEC-205–targeted
antigen elicited similar T-cell responses at more than 50-fold lower
antigen molecule numbers. Apart from EBNA1, we also investi-
gated the targeting of another EBV antigen, LMP1, to DEC-205
using LMP1-specific CD4 T-cell clones against 2 different
LCLs EFFICIENTLY PRESENT DEC-205–TARGETED ANTIGENS 1585BLOOD, 28 FEBRUARY 2013  VOLUME 121, NUMBER 9
 For personal use only. at UNIVERSITAETSSPITAL on March 8, 2013. bloodjournal.hematologylibrary.orgFrom 
SNP c115 VYG c7
KTS c37 PQC c82
HPV c35 HPV c41
Match
 A
 B
EBNA1-specific CD4+ T cell clones
Match
M
is
m
at
ch
M
at
ch
 
+ 
TI
B-
E1
+ 
αD
EC
 
+ 
αD
EC
-E
1 
+ 
Pe
pt
id
e
Match
M
is
m
at
ch
M
at
ch
 
+ 
TI
B-
E1
+ 
αD
EC
 
+ 
αD
EC
-E
1 
+ 
Pe
pt
id
e
Match
M
is
m
at
ch
M
at
ch
 
+ 
TI
B-
E1
+ 
αD
EC
 
+ 
αD
EC
-E
1 
+ 
Pe
pt
id
e
EBNA1-specific CD8+ T cell clones
LMP1-specific CD4+ T cell clones
Match
M
is
m
at
ch
M
at
ch
 
+ 
TI
B-
E1
+ 
αD
EC
 
+ 
αD
EC
-E
1 
+ 
Pe
pt
id
e
C
Match
M
is
m
at
ch
M
at
ch
 
+ 
TI
B-
E1
+ 
αD
EC
 
+ 
αD
EC
-E
1 
+ 
Pe
pt
id
e
SSH c4 LIW c1
Match
M
is
m
at
ch
M
at
ch
 
+ 
Ct
r-L
M
P1
+ 
αD
EC
 
+ 
αD
EC
-L
M
P1
 
+ 
Pe
pt
id
e
Match
M
is
m
at
ch
M
at
ch
 
+ 
Ct
r-L
M
P1
+ 
αD
EC
 
+ 
αD
EC
-L
M
P1
 
+ 
Pe
pt
id
e
0
1000
2000
3000
15000
20000
25000
IF
N
γ (
pg
/m
l)
0
2000
4000
20000
40000
IF
N
γ (
pg
/m
l)
0
5000
10000
15000
IF
N
γ (
pg
/m
l)
0
5000
10000
15000
20000
25000
IF
N
γ (
pg
/m
l)
0
10000
20000
30000
40000
IF
N
γ (
pg
/m
l)
0
5000
10000
15000
IF
N
γ (
pg
/m
l)
M
is
m
at
ch
M
at
ch
 
+ 
TI
B-
E1
+ 
αD
EC
 
+ 
αD
EC
-E
1 
+ 
Pe
pt
id
e
0
5000
10000
15000
20000
IF
N
γ (
pg
/m
l)
0
500
1000
1500
IF
N
γ (
pg
/m
l)
****
****
****
****
****
****
 **
***
Figure 1. LCLs present DEC-205–targeted EBV antigens efficiently to T-cell clones of different peptide specificities and HLA restrictions. (A) HLA-matched (Match)
LCLs for EBNA1-specific CD4 T-cell clones of 4 different epitopes (SNP, VYG, KTS, and PQC) were incubated with medium, 1 g/mL control Ig-EBNA1 ( TIB-E1),
DEC-205 without EBNA1 fusion ( DEC), DEC-205-EBNA1 ( DEC-E1) for 24 hours, or for 1 hour with epitope-specific peptide ( Peptide). An HLA mismatched target
LCL was also included into the analysis (Mismatch). T cells were incubated with these targets at an E/T ratio of 1:1. T-cell activity was determined after 18 hours by measuring
IFN released into the supernatant. (B) As in panel A, T-cell responses of EBNA1-specific CD8 T-cell clones, HPVc35 and HPVc41, were tested against LCLs incubated
without or with DEC-EBNA1. (C) HLA-matched (Match) LCLs for 2 LMP1-specific CD4 T-cell clones were incubated with medium, 1 g/mL control Ig-LMP1 ( Ctr-LMP1),
DEC-205 without LMP1 fusion ( DEC), DEC-205-LMP1 ( DEC-LMP1) for 24 hours, or for 1 hour with epitope-specific peptide ( Peptide). T-cell activity was
determined as in panel A. One representative experiment of 4 per T-cell clone is shown. Statistical analysis of all available data from 4 independent experiments was performed
by Mann-Whitney test and P values are represented as **P  .01, ***P  .005, and ****P  .0001.
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epitopes, SSH restricted through HLA-DQ6 and LIW restricted
through HLA-DR16. DEC-205-LMP1–loaded LCLs induced
strong T-cell response, whereas the control isotype fusion antibody
or DEC-205–loaded matched LCLs did not (Figure 1C). Taken
together, these results indicate that LCLs express DEC-205 and
present DEC-205–targeted antigens efficiently to T-cell clones of
different peptide specificities and HLA restrictions.
LCLs are more efficient in processing DEC-205–targeted
antigens for CD4 T-cell stimulation than mature
monocyte-derived DCs
As LCLs present DEC-205–targeted antigens efficiently to T cells
and previous reports have shown that antigens can be presented
efficiently after targeting to DEC-205 on DCs, we next compared
the targeting of antigens on LCLs and DCs. HLA-matched LCLs,
mDCs, iDCs, or B cells from the same donor were used as targets
for CD4 and CD8 T-cell clones specific for the SNP and SSH
epitopes and the HPV epitope, respectively. DEC-205 targeting of
the antigen caused a dose-dependent increase in MHC presentation
of all 3 epitopes on LCLs, mDCs, and iDCs (Figure 2A). With low
concentration of Ab or peptides, cells incubated with DEC-205-
EBNA1 or LMP1 fusion could stimulate stronger CD4 T-cell
responses than cells pulsed with the cognate peptides, this is
obvious for the SNP epitope presentation by LCLs. To our surprise,
LCLs were more efficient in processing DEC-205–targeted EBNA1
or LMP1 for CD4 T-cell stimulation at the same cell number and
antigen concentration than mature monocyte-derived DCs, this was
seen with the EBNA1 derived SNP, VYG, and PQC epitopes and
the LMP1-derived SSH epitope, as DEC-205 targeting to LCLs
stimulated higher INF release by T cells than DEC-205 targeting
to mDCs. As absolute levels of INF release are dependent on the
numbers of T cells and target cells in the assay, peptide pulsed
target cells can be used as internal assay controls, and the efficiency
of DEC-205 targeting can be evaluated in comparison to the IFN
release resulting from the same target cells pulsed with the cognate
peptide. By this measure, LCLs are more efficient than DCs in
presenting the CD4 T-cell epitopes SNP, VYG, and PQC after
DEC-205 targeting, whereas mDCs are comparable with LCLs in
presenting the SSH epitope (Figure 2A, supplemental Figure 2). On
the other hand, we observed similar levels of EBNA1-specific
CD8 T-cell responses after DEC-205 targeting to LCLs and
mDCs. Despite the low levels of IFN release from the T-cell
clones stimulated with primary B cells incubated with DEC-205-
EBNA1 or LMP1 fusion, the responses were dose dependent and
even better than responses to peptide-pulsed targets at low antigen
doses (Figure 2A, supplemental Figure 2). In addition to enhanced
antigen presentation by B cells activated through EBV infection,
primary B cells, which were activated with the toll-like receptor
(TLR) 9 agonist CpG, presented DEC-205–targeted antigen better
to EBNA1- and LMP1-specific CD4 T cells than resting B cells
(Figure 2B). This correlates with the increase in DEC-205 expres-
sion on CpG activated B cells. Further analysis of DEC-205
expression on B-cell subpopulations revealed that there is no
difference in DEC-205 expression between CD27IgD naive
B cells and CD27IgD memory B cells. Both subsets up-
regulated DEC-205 to similar levels upon CpG activation
(supplemental Figure 3A). Moreover, the addition of DEC-205-
EBNA1 did not alter surface expression of HLA-DR nor the
costimulatory molecules (CD80, CD86, and PD-L1) on resting
(data not shown) or activated naive and memory B cells (supple-
mental Figure 3B). These data suggest that DEC-205 does not
stimulate normal B cells, but activated B cells can efficiently
present antigens targeted to DEC-205.
Because LCLs were more efficient in processing DEC-205–
targeted antigens for T-cell stimulations than DCs, we investigated
whether, in addition to DEC-205–mediated antigen processing,
differential expression of costimulatory molecules could account
for the stimulating capacity of LCLs compared with mDCs. For
this, we examined the costimulatory molecules CD80, CD86, and
PD-L1 on both cell types (supplemental Figure 3C). LCLs express
higher level of CD80, whereas mDCs have higher CD86 and
PD-L1 expression, and both express comparable levels of HLA-
DR. These slight differences of costimulatory molecule expression
can probably not account for the difference in presentation of
DEC-205–targeted antigen. This notion is also supported by the
similar CD4 T-cell responses to peptide pulsed LCLs and mDCs,
whereas DEC-205–targeted antigen was much better presented to
CD4 T cells by LCLs than mDCs, especially at low antigen
concentrations (Figure 2A, supplemental Figure 2). We also
observed that DEC-205 cross-linking did not change costimulatory
molecule expression (supplemental Figure 3D). However, DCs are
well known for their potent priming of T-cell mediated immunity,
so we assessed the ability of the LCLs, DCs, and primary B cells in
stimulating T cells by allogeneic mixed lymphocyte reaction
(MLR). Mature DCs were superior to all other antigen-presenting
cell populations in eliciting proliferation of CD45ROCD62L
naive T cells. However, LCLs stimulated memory T cells
(CD45ROCD62L, CD45ROCD62L or CD45ROCD62L)
almost as efficiently as DCs. This indicated that DCs confer potent
priming of T-cell immunity, but LCLs are capable of amplifying
memory T-cell responses (supplemental Figure 3E).
LCLs retain DEC-205–targeted antigens longer than DCs
To characterize why LCLs present DEC-205–targeted antigens so
efficiently, we studied the internalization of DEC-205-EBNA1 or
DEC-205-LMP1 fusion Abs on LCLs and DCs. LCLs internal-
ized the DEC-205 fusion protein slower than DCs, but because of
higher density of DEC-205 on LCLs, larger amounts of targeted
antigen were internalized by LCLs than by DCs after 24 hours
incubation (Figure 3A). Cells kept on ice or treated with the
endocytosis inhibitor cytochalasin B retained surface levels of
DEC-205–targeted antigen similar to those observed at time point
0 minutes. This indicated that loss in staining resulted from
internalization of the DEC-205 fusion protein into the cells.
Consistent with LCLs internalizing DEC-205 slower, we found
incubation of DEC-205 fusion protein for 24 hours with LCLs
stimulated specific CD4 T-cell responses more efficiently than
incubation for only 1 hour (data not shown). Because DEC-205–
targeted antigen internalization was slower for LCLs than DCs,
we wondered whether the degradation of the DEC-205 fusion
proteins differed between LCLs and DCs. For this purpose the
respective antigen presenting cells were incubated with DEC-
205-LMP1, washed, and then DEC-205-LMP1 protein levels
were assayed by immunoblotting with mAb specific for LMP1.
LCLs retained more DEC-205-LMP1 protein than mDCs and
iDCs, the targeted antigen was most rapidly degraded by iDCs,
and slowest by LCLs. As the antigen is longer retained by LCLs,
they might be able to continuously load MHC molecules for
T-cell stimulation, long after the antigen has been entirely
degraded in DCs.
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Figure 2. DEC-205 targeting of EBV antigens to LCLs stimulates better antigen-specific CD4 T-cell responses than targeting to DCs. (A) HLA-matched LCLs,
mDCs, iDCs, or B cells from the same donor were treated with the indicated concentration of control antibody, or DEC-205 with EBNA1 or LMP1 fusion, or peptide, then
incubated with the corresponding matched EBNA1- or LMP1-specific T-cell clones. T-cell responses were measured as IFN release after 18 hours of coculture at an E/T ratio
of 1:1. (B) HLA-matched CD19 B cells were incubated with 1 g/mL control antibody with EBNA1 or LMP1 fusion, DEC-205-EBNA1 or LMP1 fusion, DEC-205-EBNA1 or
LMP1 fusion with or without 2.5 g/mL CpG for 24 hours, or for 1 hour with epitope-specific peptide, then incubated with EBNA1- or LMP1-specific CD4 T cells. T-cell activity
was determined as in panel A. One of 2 experiments per T-cell clone is shown. P values were calculated from the data of 2 independent experiments with Mann-Whitney test
and are represented as **P  .01.
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Figure 3. LCLs retain DEC-205–targeted antigen longer than DCs. (A) LCLs, mDCs, or iDCs were incubated with 1 g/mL control Ig-EBNA1 or DEC-205-EBNA1 on ice for
30 minutes. Cells were then washed and incubated at 37°C for the indicated time periods. As a control for internalization, cells were left on ice or incubated with 10M
cytochalasin B (cyto B) in addition to DEC-205-EBNA1 pulsing. Cells were then stained with PE-conjugated anti-mouse antibody. Data are mean values plus SD from
3 independent experiments and relative internalization is shown as percent maximum. (B) LCLs, mDCs, or iDCs were incubated without (ve) or with 4 g/mL
DEC-205-LMP1 on ice for 30 minutes. Cells were then washed and incubated at 37°C or left on ice as a control. Cell samples were lysed at the indicated time points and
frozen. Protein lysates were separated by SDS/PAGE, transferred to PVDF membranes for Western blotting, and probed with a LMP1-specific mAb. Blots were also probed for
actin as a loading control. One representative blot of 3 experiments is shown; mean values plus SD of relative protein content and percentage maximum from 3 independent
experiments are also shown.
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DEC-205 and B-cell receptor both deliver antigens to
endolysosomal compartments in LCLs
Because the BCR is considered the main antigen uptake receptor
for efficient antigen processing by B lymphocytes, we wondered
whether it targeted antigens to endosomes similar to those reached
by DEC-205–targeted antigens, which could explain the efficient
MHC presentation of targeted antigens. For this, we performed
confocal immunofluorescence microscopy to analyze the intracellu-
lar location of DEC-205 after internalization by LCLs or mDCs.
Colocalization with transferrin receptor or lysosomal-associated
membrane protein 2 (LAMP-2), as markers for early and late
endosomes, respectively, was investigated. Internalized DEC-205
was found in both early and late endosomes; control cells fixed
immediately after exposure with DEC-205 only showed surface
staining as expected (Figure 4A). The colocalization was quantified
and Pearson coefficients were determined. DEC-205 was en-
riched in LAMP-2–positive endosomes in both LCLs and mDCs,
and DEC-205 demonstrated slightly higher colocalization with
LAMP-2 in LCLs than mDCs (Figure 4B), possibly because of
more rapid degradation of DEC-205–targeted protein in mDCs.
These data confirm preferential DEC-205 targeting to late endo-
somes in human cells.26 Moreover, DEC-205 partially colocalized
with BCRs internalized after cross-linking, primarily in late
endosomes (Figure 5). These findings suggest that DEC-205–
targeted antigens are delivered to late endosomal compartments for
efficient processing and loading onto MHC class II molecules,
similar to antigens cross-linking the BCRs.
B cells play a role in amplifying antigen-specific CD4 T-cell
response on DEC-205 targeting in vivo
DEC-205 targeting of antigen to activated B cells led to efficient
antigen presentation to both CD4 and CD8 T cells in vitro. Thus,
we investigated whether B cells play a role in stimulating
antigen-specific T-cell response on antigen targeting to DEC-205
in vivo. We immunized B-cell deficient JHT/ (JHT) mice27 and
their wild-type C57BL/6 counterparts with engineered mAbs
against mouse DEC-205 with a HIV gag p24 fusion protein
(DEC-205-p24).28 The TLR 3 ligand polyIC was used as the
adjuvant and an IgG-p24 fusion protein served as the isotype
control. Antigen-specific T-cell responses were evaluated by IFN
production in response to HIV gag p24 peptide mix by multicolor
flow cytometry. Mice immunized with DEC-205-p24 plus polyIC
had gag p24-specific IFN-producing CD4 T-cell responses. No
Figure 4. Intracellular localization of DEC-205 in
LCLs and mDCs. (A) LCLs and mDCs were incubated
withDEC-205, washed and incubated for 0 or 30 minutes at
37°C. Cells were then permeabilized, fixed, and stained
with antibodies to transferrin receptor (TR) or lysosomal-
associated membrane protein 2 (LAMP-2), DEC-205
(DEC), and DAPI. Scale bars represent 5 m. Representa-
tive cells from 1 experiment of 3 are shown. (B) Quantitative
analysis for colocalization of DEC-205 with TR and
LAMP-2 in LCLs and mDCs loaded with DEC-205 and
incubated for 30 minutes at 37°C. Fifteen to 20 cells were
analyzed from 1 independent experiment, data represent
means from 50 to 60 cells from 3 experiments. Error bars
indicate SD.
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significant CD4 T-cell immunity was observed after immuniza-
tion with isotype control mAb plus polyIC and DEC-205-p24
without polyIC (Figure 6). These data confirm previous results.6,29
In addition, no significant CD8 T-cell immunity could be detected
in the immunized mice (data not shown), which could be induced
by the addition of CD40 as adjuvant.6 Interestingly, C57BL/6
mice with an intact B-cell compartment, which were immunized
with DEC-205-p24 with polyIC, exhibited significantly stronger
gag p24-specific CD4 T-cell responses compared with B-cell
deficient mice with the same immunization (Figure 6). However,
C57BL/6 and JHT mice both had comparable T-cell responses on
CD3 and CD28 stimulation (data not shown). This data indi-
cated that B cells play a role in amplifying antigen-specific CD4
T-cell response on antigen targeting to DEC-205 in vivo. Next, we
analyzed whether this amplification would lead to a more ex-
hausted HIV gag p24-specific CD4 T-cell response by C57BL/6
and JHT mice immunized with DEC-205-p24 plus polyIC, by
examining PD1 expression on these T cells. We did not see any
difference in PD1 expression on gag p24-specific CD4 T cells
between the wild-type and JHT mice (data not shown). Therefore,
targeting antigens to DEC-205 on B cells does not seem to promote
the exhaustion of antigen-specific T cells.
Apart from investigating the IFN production for evaluating the
immunization, we also tested the proliferation of antigen-specific
T cells on restimulation with gag p24 peptide mix by CFSE
dilution. Because of the limited amount, we had to pool splenocytes
of mice from the same immunized group. We depleted the CD19
B cells from splenocytes of the wild-type mice so that the amount
of antigen presenting cells would be similar to splenocytes from
JHT mice. Stronger CD4 T-cell proliferation against gag p24 peptide
stimulation was observed in C57BL/6 mice immunized with
DEC-205-p24 plus polyIC than JHT mice with the same immuni-
zation (supplemental Figure 4B), which correlates with the results
observed in IFN production (Figure 6). Taken together, B cells
seem to play a role in amplifying antigen-specific CD4 T-cell
response on antigen targeting to DEC-205 in vivo.
Discussion
Targeting antigens to DCs by incorporating specific microbial or
tumor antigens into antibodies against the endocytic receptor,
DEC-205, on DCs is a promising strategy for therapeutic vaccina-
tions.5,7,24,30 Although this strategy was originally intended to only
deliver antigen to DCs, B cells might play an important role in
amplifying primed T-cell responses by retaining and loading
DEC-205–targeted antigens for MHC presentation. Here, we
demonstrated that human B cells, especially activated B cells, such
as LCLs, express high levels of DEC-205 and efficiently process
DEC-205–targeted antigen for MHC presentation (Figure 1, supple-
mental Figure 1). Surprisingly, LCLs are more efficient in present-
ing DEC-205–targeted antigens to CD4 T cells than mature
monocyte-derived DCs (Figure 2). However, mature DCs were
superior to all other antigen-presenting cell populations in priming
naive T cells (supplemental Figure 3). This suggested that DCs
confer potent priming of T-cell immunity, whereas LCLs are
capable of amplifying memory T-cell responses. Along these lines
we previously demonstrated that EBV-transformed B cells stimu-
late, and are efficiently controlled by, peripheral blood T cells of
Figure 5. DEC-205 and B-cell receptor deliver antigens
in LCLs with partial colocalization. LCLs were incu-
bated with DEC-205 and biotinylated F(ab)2 anti-IgM Ab
for 2 hours, washed, permeabilized, fixed, and stained
with antibodies to transferrin receptor (TR) or lysosomal-
associated membrane protein 2 (LAMP-2), DEC-205
(DEC), IgM (BCR), and DAPI. Scale bars represent
5 m. Representative cells from 1 experiment of 3 are
shown. (B) Quantitative analysis for colocalization of
DEC-205 (DEC) with IgM (BCR) in LCLs incubated with
DEC-205 and IgM for 30 minutes at 37°C. Fifteen to
20 cells were analyzed from 1 independent experiment,
data represent means from 50 to 60 cells from 3 experi-
ments. Error bars indicate SD.
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EBV-seropositive donors in vitro, whereas cells from EBV-
seronegative donors require bystander DCs to cross-prime protec-
tive T-cell response.31 As healthy EBV carriers have latency III
expressing LCL-like cells in their tonsillar naive B-cell compart-
ment,32 and LCL-like cells are the dominant population of EBV
infected B cells in the tonsils of the affected individuals during
acute infection,33 EBV infected B cells, such as LCLs, may play a
role in augmenting MHC presentation of DEC-205–targeted anti-
gens in vivo.
Extending these findings to an animal model, antigen targeting
to DEC-205 led to reduced expansion of CD4 T cells in B cell–
deficient JHT mice (Figure 6), demonstrating the role of B cells in
amplifying DC-induced immune responses in vivo. Although
protein-based vaccine development targeting DCs has been ex-
tended from DEC-205 to other C-type lectin receptors, such as
Clec9A34 or langerin,35 which are more restricted to DCs, our data
suggest that it may be beneficial to target a receptor that is not only
expressed on DCs, but also on other antigen presenting cells, to
harness this immune response amplification. Additional targeting
to B cells might also improve humoral immune responses. It was
recently reported that depletion of CD11c cells had no effect on
antibody responses but impaired T-cell immunity after targeting
antigen to DEC-205 for immunization.36 Furthermore, germinal
center B cells in mouse spleen express high level of DEC-205.22
The effect of antigen targeting to DEC-205 on humoral immune
response needs further investigation.
In addition, B cells might constitute an antigen reservoir for
prolonged antigen presentation after DEC-205 targeting. We were
surprised by the observation that LCLs process DEC-205–targeted
antigens more efficiently for CD4 T-cell stimulation than mature
monocyte-derived DCs. Our study on internalization and degrada-
tion of DEC-205 on LCLs and DCs indicated that LCLs retain
DEC-205–targeted antigen longer than DCs (Figure 3). A similar
difference was observed between DCs and macrophages. Macro-
phages were found to degrade injected antigen more rapidly in vivo
than DCs, correlating with a more superior and sustained antigen
presentation by DCs.37 Interestingly, when antigen was rendered
more resistant to lysosomal degradation, it was more efficiently
presented to CD4 T cells.38 In addition, DCs seem to limit
lysosomal degradation in phagosomes for their superior antigen
presentation by various mechanisms, including attenuated acidifica-
tion.39 Thus, the enhanced ability of B cells to present DEC-205–
targeted antigen may reflect the slower rate of degradation exhib-
ited by these cells.
Figure 6. B cells play a role in amplifying antigen-specific CD4 T-cell responses toward DEC-205–targeted antigen in vivo. (A) C57BL/6 mice or the B-cell deficient
JHT mice were immunized with 5 g of isotype control fusion mAb with 50 g polyIC (IgG-p24  polyIC), or DEC-205 mAb conjugated with HIV gag p24 (DEC-p24) without
or with 50 g polyIC (DEC-p24  polyIC) as adjuvant, and boosted 1 month later. The mice were killed a week after boost, bulk splenocytes were harvested, stimulated with
either gag p24 peptides or gag p17 peptide mix, IFN production was evaluated by intracellular cytokine staining in the CD3CD4 gated cells. (B) As in panel A, mean 	 SD
from 2 independent experiments with 3 mice per group is shown. P value was calculated with 2-tailed Student t test.
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Our data also suggested that apart from the BCR, the endocytic
receptor DEC-205 can mediate efficient antigen processing for
MHC class II presentation on B cells. DEC-205–targeted antigens
are delivered to late endosomal compartments for efficient process-
ing and loading onto MHC class II molecules, similar to antigens
that are cross-linking the BCR (Figure 5) on B cells. In fact, BCR
targeted antigen is retained by B cells in late endosomal compart-
ments,40 some of which can even fuse with TLR containing
endosomes for both antigen loading onto MHC class II molecules
and B-cell activation.41,42 Although this targeting to late endosomal
compartments is beneficial for MHC class II loading, it might,
however, compromise cross-presentation onto MHC class I mol-
ecules via escape of the antigen from endosomes. Indeed, although
the cross-presenting vesicular compartment is still ill-defined, early
endosomes seem to potently promote cross-presentation of endocy-
tosed antigens.43,44 In contrast, DEC-205–targeted antigen gets
efficiently transported to late endosomes in mouse26 and human
cells (this study), and therefore might favor antigen processing for
MHC class II presentation over class I presentation. Accordingly,
the preference of DEC-205–targeted antigen to stimulate CD4
T cells that we observed in our study, was also noticed with most,
particularly pathogen derived antigens in mouse studies in
vivo.28,29,45 Thus, the intracellular localization of the targeted
antibodies may explain why both DEC-205 and BCR targeting lead
to more efficient MHC class II presentation than class I presentation.
In conclusion, antigen targeting to DEC-205 was originally
intended to only deliver antigen to DCs, but we have shown here
activated B cells might amplify primed T-cell responses by
processing DEC-205–targeted antigens for MHC presentation.
This dual targeting function of DEC-205 directed antigens might be
beneficial for vaccination.
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